Myriad Genetics Shares Drop as CEO Resigns, Sales Fall Short
This article is for subscribers only.
Myriad Genetics Inc. shares plunged after the DNA-testing company said its top executive would depart amid a steep drop in sales.
The company said in a news release on Thursday that Chief Executive Officer Mark C. Capone had resigned and was being replaced, effective immediately, by the company’s chief financial officer, R. Bryan Riggsbee.